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Concise Communication
Development and validation of a bedside instrument to predict
carbapenem resistance among gram-negative pathogens in
complicated urinary tract infections
Marya D. Zilberberg MD, MPH1,2, Brian H. Nathanson PhD3, Kate Sulham MPH4,5, Weihong Fan MS4 and
Andrew F. Shorr MD, MPH6
1EviMed Research Group, Goshen, Massachusetts, 2Universtiy of Massachusetts, Amherst, Massachusetts, 3OptiStatim, Longmeadow, Massachusetts,
4The Medicines Company, Parsippany, New Jersey, 5Melinta Therapeutics, Lincolnshire, Illinois and 6Washington Hospital Center, Washington, DC
Abstract
We developed a bedside instrument to predict carbapenem resistance in complicated urinary tract infections. A model assigning weighted
points for admission from an extended care facility (1), history of weight loss (1), early mechanical ventilation (1), age <50 years (2), male
gender (3), catheter-associated urinary tract infection (4), prior antibiotics treatment (4), and prior carbapenem-resistant infection (8)
exhibited good discrimination (C statistic, 0.721).
(Received 26 March 2018; accepted 8 June 2018; electronically published July 31, 2018)
Carbapenem resistance has arisen with alarming speed.1,2 Currently,
>3% of Enterobacteriaceae are carbapenem nonsusceptible, and
rates among Pseudomonas aeruginosa and Acinetobacter baumannii
are substantially higher, making it difficult for clinicians to select
initially appropriate empiric coverage for patients presenting with
serious infections.3,4 Although rapid diagnostic testing promises to
improve early antimicrobial therapy targeting, it presents certain
limitations and cannot be utilized without some assessment of
pretest probability for resistance.5 A predictive tool based on clinical
factors for risk stratification is necessary either as an adjunct to or a
substitute for rapid diagnostic testing.
Methods
We developed a bedside score to predict the risk for carbapenem
resistance within a multicenter retrospective cohort of hospitalized
patients with complicated urinary tract infection (cUTI) diagnosis
and a culture positive for P. aeruginosa, A. baumannii, Steno-
trophomonas maltophilia (assumed always to be carbapenem
resistant), or Enterobacteriaceae (see Supplemental Material).
Because this study used fully deidentified retrospective data, it was
exempt from institutional review board review.
Adult patients with a cUTI fitting our enrollment criteria were
included (see Supplemental Material for enrollment criteria and
identification algorithms). The data for the study were extracted
from the Premier Research database, an electronic laboratory,
pharmacy, and billing data repository, for 2009–2016 (through
the third quarter of 2006), which contains ~15% of all hospita-
lizations nationwide. (A detailed description of the database is
available in Zilberberg et al.3,4) We used data from 178 US
institutions submitting microbiology data into the database.
Carbapenem resistance was defined as a cultured organism
designated as intermediate or resistant to imipenem, meropenem,
ertapenem, or doripenem. A carbapenem-susceptible organism
was an organism susceptible to either any carbapenem tested or to
any third-generation cephalosporin (see Supplemental Material).
First detection of a carbapenem-resistant organism (or a
carbapenem-susceptible organism of interest in the absence of
carbapenem resistance) served as the index culture. Empiric
antibiotic treatment was considered appropriate when coverage
within 2 days of the culture being obtained included the
corresponding organism. All other regimens were deemed inap-
propriate empiric treatment. A cUTI was classified as community
onset if it was present on admission or if an index culture was
obtained within the first 2 hospital days.
Statistical analyses
We compared the carbapenem-resistant group to the carbapenem-
susceptible group with respect to demographics, comorbidities,
hospital characteristics and processes, and outcomes. To develop a
logistic regression to predict the presence of carbapenem resistance,
we used a split-cohort method, with 60% allocated to the training
cohort and 40% to the validation cohort. We then pared the model
to 10 predictors or fewer for the ease of the end user. Terms were
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culled based on the factor’s prevalence and its contribution to the
model’s predictive ability in the development cohort using a step-
wise bootstrapping algorithm and Bayesian information criterion in
a series of nested models.6 We assessed the model’s discrimination
with the C statistic and calibration visually in a plot of observed
versus expected risk deciles and with the Hosmer-Lemeshow sta-
tistic. We then developed a score considering the weight of each
factor’s regression coefficient to predict the presence of a
carbapenem-resistant organism.
Results
Among 25,285 patients with cUTI, 23,469 patients (92.8%) had a
community-onset UTI and 1,357 (5.4%) had a UTI caused by a
carbapenem-resistant organism. Baseline characteristics, micro-
biology, and hospital events can be found in the Supplemental
Material Tables 5–7.
Unadjusted mortality (3.7% vs 2.3%; P< .001) and 30-day
readmission (24.3% vs 18.0%; P< .001) were higher in the setting
of carbapenem resistance than carbapenem susceptibility. Unad-
justed median hospital costs were also greater among patients
with carbapenem-resistant infections those with carbapenem-
susceptible infections: $10,356 (interquartile range [IQR],
$6,509–$18,674 versus $8,613 (IQR, $5,241–$15,316), respectively
(P< .001). Postinfection-onset hospital lengths of stay were also
longer among patients with carbapenem-resistant infections than
those with carbapenem-susceptible organisms: 5 days (IQR,
3–9 days) versus 4 days (IQR, 2–7 days), respectively (P< .001).
In a model designed to predict the likelihood of carbapenem
resistance in this population, we assigned weighted points pro-
portional to the regression coefficients of the following factors:
admission from an extended-care facility (1), history of weight
loss (1), early mechanical ventilation (1), age <50 (2), male gender
(3), catheter-associated UTI (4), prior antibiotics treatment (4),
and prior carbapenem-resistant infection (8). The model exhib-
ited good discrimination in both the training (C statistic, 0.746)
and validation (C statistic, 0.721) sets. It performed better among
hospitals with lower prevalence of carbapenem resistance, as
evidenced by a C-statistic drop with an increase in carbapenem
resistance prevalence in the validation set: tertile 1, 0.752 (pre-
valence of carbapenem resistance, 2.1%); tertile 2, 0.725 (pre-
valence of carbapenem resistance, 4.7%); and tertile 3, 0.703
(prevalence of carbapenem resistance, 9.2%).
The distribution of patients within specific score ranges with
the corresponding proportions of carbapenem resistance is shown
in Fig. 1. While most of the cohort (86.5%) fell under 10 points,
nearly 15% of those patients with the score of 10 points or more
harbored a carbapenem-resistant organism. Conversely, patients
whose score was below 3, which accounted for 29.9% of all the
patients in the cohort, had a ~1% risk of a cUTI caused by a
carbapenem-resistant organism.
Discussion
In a cohort of hospitalized patients with a cUTI (>5% carbape-
nem resistant), we developed a bedside predictive score that, by
virtue of its high negative predictive value in the low score ranges,
may be useful in helping clinicians rule out the need for empiric
coverage for a carbapenem-resistant organism in a cUTI.
Although we did not limit our cohort to community-onset
infections, the vast majority of the admissions (>92%) had cUTI
present on hospital day 1. The small fraction of cUTIs that
occurred as a nosocomial complication reflects well on hospital
infection control interventions aimed at preventing such com-
plications but also highlights the importance of considering the
risk of a carbapenem-resistant organism even among patients
from a community setting. Other investigators have noted this
phenomenon in multiple pathogen classes, and we confirm its
importance.7–10
Previous investigations have demonstrated that the presence of
resistance alone does not determine the outcome.3,4 Rather,
whether the patient receives appropriate initial antibiotic regimen
has a greater effect. Our score, though aiming to aid with such
risk stratification, does not have perfect precision. However, when
combined with knowledge of local resistance patterns and hos-
pital antibiograms, it should facilitate efforts to ensure that
patients with cUTIs receive appropriate empiric treatment.
Moreover, our risk score helps to reinforce efforts toward anti-
microbial stewardship by identifying when coverage for
carbapenem-resistant pathogens in this syndrome is clearly not
appropriate. Therefore, if applied correctly, this tool can help
limit indiscriminate use of certain broad-spectrum antimicrobials.
Our study has a number of strengths and limitations. As a large
multicenter cohort it is representative of US institutions, and thus
has broad generalizability. Although our findings are susceptible to
selection bias, we mitigated it by setting a priori enrollment criteria
and definitions. Though some misclassification is possible, our cUTI
algorithm was designed to maximize the specificity of the diagnosis,
and carbapenem resistance conformed to a standard definition.
In summary, the bulk of cUTI admissions are community
onset, and carbapenem-resistant pathogens account for >5% of
all gram-negative organisms at risk for developing carbapenem
resistance. Until rapid diagnostics are ready for widespread use,
we may need to settle for imperfect but helpful probabilistic
models like ours to help identify, if not patients at high risk for
resistance, those whose low probability of a resistant organism
combined with other aspects of the clinical picture makes
narrower-spectrum agents an adequate first choice for treatment.
Supplementary material. To view supplementary material for this article,
please visit https://doi.org/10.1017/ice.2018.166
Fig. 1. Prediction score for carbapenem resistance in cUTI. Note. cUTI, complicated
urinary tract infection; CR, carbapenem resistant.
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